Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics (KYMR) stock hits a new 52-week high driven by positive clinical trial data and strong social media buzz. Analysts are bullish on the biotech sector, with significant engagement surrounding KYMR's drug development.

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for immuno-inflammatory diseases.
Kymera Therapeutics, Inc. uses the ticker $KYMR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Kymera Therapeutics, Inc. (KYMR) social dominance hit [------] which is 321% higher than it's daily average.
Kymera Therapeutics, Inc. (KYMR) engagements is up 174.31% from the previous [--] months.
Kymera Therapeutics, Inc. (KYMR) posts created is up 26.32% from the previous week.

Price: $82.30

Price 24-Hour Time-Series Raw Data
The stock price has reached a 52-week and all-time high, driven by positive clinical trial data, favorable analyst ratings, and significant social media activity, despite a recent dip.

24-Hour: -2.72% 7-Day: 3.46% 30-Day: 18.41%

1-Year High: $94.30 on 2025-12-08
1-Year Low: $21.10 on 2025-04-08

AltRank: [---]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Kymera Therapeutics, Inc. (KYMR) is currently AltRank #806 based on combined combined social and market metrics Daily Average: [---]
[--] Week: [---] [----]
[--] Month: [---] +437
[--] Months: [---] +361
[--] Year: [---] +131
1-Year High: [-----] on 2025-02-27
1-Year Low: [--] on 2025-07-06

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-12-08
1-Year Low: [--] on 2026-01-11

Engagements: [-----] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [-------] +159%
[--] Month: [-------] +44%
[--] Months: [---------] +36%
[--] Year: [---------] +146%
1-Year High: [-------] on 2025-12-08
1-Year Low: [---] on 2025-04-20

Engagements by network (24h): News: [--] TikTok: [--] X: [-----] Reddit: [--] YouTube: [--]

Mentions: [--] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [---]
[--] Week: [---] -4.20%
[--] Month: [---] +23%
[--] Months: [-----] -25%
[--] Year: [-----] +268%
1-Year High: [-----] on 2025-07-06
1-Year Low: [--] on 2025-04-18

Mentions by network (24h): News: [--] TikTok: [--] X: [--] Reddit: [--] YouTube: [--]

Creators: [--] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Kymera Therapeutics, Inc. (KYMR) in the last [--] hours which is down 13% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [---] -16%
[--] Month: [---] -4.50%
[--] Months: [-----] -33%
[--] Year: [-----] +309%
1-Year High: [---] on 2025-07-06
1-Year Low: [--] on 2025-02-23

The most influential creators that mention Kymera Therapeutics, Inc. in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@HOThomasWPhelps	[--]	[-----]	[--]	[-----]
@tradingsssss	[--]	[-----]	[--]	[---]
@Andre_AGTC	[--]	[-----]	[--]	[---]
@chaotropy	[--]	[---]	[--]	[---]
@BuyTheUgly	[--]	[--]	[--]	[---]
@semodough	[--]	[------]	[--]	[--]
@barronsonline	[--]	[-------]	[--]	[--]
@financebully	[--]	[-----]	[--]	[--]
@mariostario2019	[--]	[--]	[--]	[--]
@doepke_michel	[--]	[-----]	[--]	[--]

Sentiment: 94%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 94%
Daily Average: 73%
[--] Week: 100% +8%
[--] Month: 86% +19%
[--] Months: 86% +5%
[--] Year: 86% no change
1-Year High: 100% on 2025-02-23
1-Year Low: 23% on 2025-04-13

Most Supportive Themes:

Positive Analyst Commentary and Biotech Sector Outlook: (40%) Analysts are discussing Kymera's approach and comparing it to competitors, with positive sentiment around the biotech sector.
Mentions of KYMR in conjunction with other Biotech Stocks: (30%) Posts frequently mention KYMR alongside other biotech stocks, indicating potential sector-wide interest and comparisons.
Positive Sentiment and High Engagement on Social Media: (20%) Overall sentiment is positive, with high engagement on posts mentioning KYMR, especially from influential creators.

Most Critical Themes:

Concerns about Efficacy and Side Effects: (10%) Some posts raise concerns about the efficacy of KYMR's treatments compared to competitors and potential side effects.

Social Dominance: 0.00684%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00684%
Daily Average: 0.015%
[--] Week: 0.00717% -0.0005300000000000001%
[--] Month: 0.063% +0.054%
[--] Months: 0.063% +0.052%
[--] Year: 0.063% +0.057%
1-Year High: 0.169% on 2025-07-06
1-Year Low: 0.0029% on 2025-04-08

Market Dominance: 0.00746%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00746%
Daily Average: 0%
1-Year High: 0.009% on 2025-12-08
1-Year Low: 0.00227% on 2025-04-08

Market Cap: $6,587,119,883

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $6,587,119,883
Daily Average: $3,695,214,948
[--] Week: $6,591,119,835 +4.30%
[--] Month: $6,587,119,883 +18%
[--] Months: $6,587,119,883 +118%
[--] Year: $6,587,119,883 +176%
1-Year High: $7,543,908,246 on 2025-12-08
1-Year Low: $1,367,074,063 on 2025-04-08

Top Kymera Therapeutics, Inc. Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"$NKTR $CRVS $APGE $KYMR $EVMN why are we even trying to compete with one another 😂 $NKTR $CRVS https://t.co/cJhhh1lPTx $NKTR $CRVS https://t.co/cJhhh1lPTx"
X Link @tradingsssss 2026-02-15T08:45Z [----] followers, [----] engagements

"Summary graphic of atopic dermatitis drugs/targets by benefit/treatment profile: SOC benchmarks: #Dupilumab $SNY $REGN and #Upadacitinib $ABBV Compare to: Injectables in Ph2b trials #APG777 $APGE #Rezpeg $NKTR Oral drugs in Ph2b trials #soquelitinib $CRVS KT-621 $KYMR @JoseRestonVA It's a smart bet I have a slightly different perspective on it: Dupi's [----] LOE will be unique in a way where they will still be a Best in Disease gold standard product. When dupi biosimilars come into the market they will be widely used bc of this gold standard efficacy and @JoseRestonVA It's a smart bet I have a"
X Link @HOThomasWPhelps 2026-02-14T16:24Z [----] followers, [----] engagements

"Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://twitter.com/i/web/status/2022331133032100249 https://twitter.com/i/web/status/2022331133032100249"
X Link @HOThomasWPhelps 2026-02-13T15:24Z [----] followers, [----] engagements

"$CRVS oral ITK inhibitor #soquelitinib AD profile: Works fast as JAKi + EASI-75 benefit months off-treatment Oral therapy in just 4-8 wks offers $ABBV JAKi disease control but better safety + $NKTR #Rezpeg duration Also works in patients that fail #Dupilumab or #Upadacitinib 🚨 Table of Drug Profiles for Different Treatments/Targets in Atopic Dermatitis FDA-approved and In-Development $ABBV $AMGN $APGE $BMY $CRVS $KYMR $LLY $NKTR $PFE $REGN $SNY https://t.co/0x2HOgjhuN 🚨 Table of Drug Profiles for Different Treatments/Targets in Atopic Dermatitis FDA-approved and In-Development $ABBV $AMGN"
X Link @HOThomasWPhelps 2026-02-13T07:10Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing